Gan & Lee Pharmaceuticals is a Chinese biopharmaceutical company specializing in insulin analogs and biosimilar peptides, with a leading share of China's domestic insulin market. In addition to its diabetes franchise, the company has expanded into metabolic disease and obesity with next-generation GLP-1 / dual-agonist programs. In June 2026, Gan & Lee reported positive Phase 3 results for its obesity peptide candidate and is preparing to expand outside of China through partnerships and licensing deals.
Company Info
Upcoming Milestones & Key Dates
NDA filing for obesity GLP-1 / glucagon dual agonist in China
Western partnership / licensing announcements for obesity peptide
Clinical Development Pipeline
Recent News
Chinese insulin-maker Gan & Lee reported positive Phase 3 results for its biosimilar and next-generation obesity peptides, while Johnson & Johnson highlighted multiple myeloma combination data at EHA 2026.
Leadership Team
Chairman and President
Founder and Chairman (former)
Careers & Job Openings